- Japan’s Suspension of Recommendation for Gardasil & Cervarix HPV Vaccines for Women – Caused by Large Numbers of Unexplained Serious Adverse Reactions
- US Bill [Albany, NY] To Allow US 4 Year Olds To Opt Into Anti-Sexually Transmitted Disease Vaccines – Blocked Temporarily
SaneVax is an international non-profit organization working with representatives in over 25 countries. SaneVax believes vaccines should be scientifically proven safe, affordable, necessary and effective. The SaneVax Team say they cannot support HPV vaccination programs for the following reasons:
#1 HPV VACCINES ARE NOT SAFE
- HPV vaccines account for nearly 25% of the reports on the USA’s Vaccine Adverse Event Reporting System (VAERS) database. VAERS was established in 1990. HPV vaccines were introduced 16 years later in mid-2006. And there are over 80 other vaccines approved for use in the United States. Since the introduction of HPV vaccines [including Gardasil and Cervarix]:
- reports of Acute Disseminated Encephalomyelitis [ADEM] have increased over 1,000%;
- infertility reports increased 790%;
- reports of blindness increased 188%;
- spontaneous abortions by 270%.
- when 24,000 girls were injected with HPV vaccines during ‘demonstration projects’ an estimated 5% (1200) were left with chronic health problems and/or autoimmune disorders;
- Japan withdrew the government recommendation for the administration of HPV vaccines after only 6 weeks when reports of adverse events after Gardasil were 26 times higher than the annual flu shot;
- reports after Cervarix were 52 times higher than the annual flu shot;
- 24.9% of the adverse events reported were considered serious.
- Denmark reports that 24% of the adverse events reported after HPV vaccinations were considered serious.
- adverse events reports in Italy are ten times higher than most other vaccines – at a rate of 219/100,000. The cervical cancer rate in Italy is 7.7/100,000.
#2 HPV VACCINES ARE NOT AFFORDABLE
- HPV vaccination programs do not eliminate the need for pap screening, they simply add the price of 3 injections to already overburdened healthcare systems around the globe.
- There is an already proven safe and effective method of controlling cervical cancer in most developed countries – pap screening and good gynecological follow-up. Countries without this practice in place would be money ahead to spend their healthcare budget developing the infrastructure to provide this type of care.
- Cervical cancer causes 2.3 deaths/100,000 women in the United States. The cost of 3 doses of HPV vaccine for 100,000 women is an estimated $30,000,000 ($100/dose) to try and eliminate less than 3 deaths which could have been avoided with pap screening and good gynecological follow-up. How many medical professionals could be trained and/or medical facilities built with that same 30 million dollars?
#3 HPV VACCINES ARE NOT NECESSARY
- The human papillomavirus has never been proven to cause cancer by itself. Other risk factors must also be present in order to prompt the development of cancer.
- According to the World Health Organization, only 0.15% of all people exposed to any high-risk strain of HPV will ever develop cervical cancer. The vast majority of HPV ‘infections’ are benign and cause no medical problem whatsoever.
- HPV type prevalence varies greatly from one region to the next. Are the HPV types targeted by current vaccines the same ones prevalent in your country?
- There is no excuse for exposing the female population of the world to the risks involved with HPV vaccination when there is an already proven safe, affordable, necessary and effective means of controlling cervical cancer.
#4 HPV VACCINES ARE NOT EFFECTIVE
- According to the World Health Organization, only 1% of CIN1 progresses to the next stage, only 1.5% of CIN2 progresses. Only 12% of CIN3 lesions, which are actually considered a pre-cursors to cancer. Nevertheless, the FDA allowed the manufacturers of HPV vaccines to use these often self-reversing abnormal lesions as endpoints to judge the efficacy of their products.
- The other endpoint used to predict efficacy was antibody titers. No one has determined what level of antibodies is necessary to prevent HPV infections. It is simply assumed that the higher the antibody titer level, the better the potential protection.
- HPV vaccines have not been clinically proven to prevent a single case of cancer.
- There is no guarantee that eliminating one risk factor for the development of cervical cancer will have any impact on the disease incidence or mortality rate.
- It will take more than 20 years to determine whether or not HPV vaccines perform as advertised.
- There is no guarantee that any suppressed oncogenic HPV type will not mutate over the next 20 years and become more dangerous.